FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129432386> ?p ?o ?g. }

• W2129432386 endingPage "6501" @default.
• W2129432386 startingPage "6487" @default.
• W2129432386 abstract "Abstract Purpose: The epidermal growth factor receptor (EGFR) is abnormally activated in cancer and two classes of anti-EGFR agents, monoclonal antibodies and low-molecular-weight tyrosine kinase inhibitors, have shown antitumor activity in patients. Because these two classes of antireceptor agents target the EGFR at different sites, we decided to explore whether the combined administration of gefitinib, a tyrosine kinase inhibitor, and cetuximab, a monoclonal antibody, had superior antitumor activity than either agent given alone. Experimental Design: We studied the effects of the combination of gefitinib and cetuximab in a panel of human cancer cell lines and in an EGFR-dependent human tumor xenograft model (A431). The effects of these two agents on EGFR signaling, proliferation, apoptosis, and vascularization were evaluated. In addition, we analyzed, with cDNA arrays, changes in gene expression profiles induced by both agents. Results: The combined treatment with gefitinib and cetuximab resulted in a synergistic effect on cell proliferation and in superior inhibition of EGFR-dependent signaling and induction of apoptosis. In a series of in vivo experiments, single-agent gefitinib or cetuximab resulted in transient complete tumor remission only at the highest doses. In contrast, suboptimal doses of gefitinib and cetuximab given together resulted in a complete and permanent regression of large tumors. In the combination-treated tumors, there was a superior inhibition of EGFR, mitogen-activated protein kinase, and Akt phosphorylation, as well as greater inhibition of cell proliferation and vascularization and enhanced apoptosis. Using cDNA arrays, we found 59 genes that were coregulated and 45 genes differentially regulated, including genes related to cell proliferation and differentiation, transcription, DNA synthesis and repair, angiogenesis, signaling molecules, cytoskeleton organization, and tumor invasion and metastasis. Conclusions: Our findings suggest both shared and complementary mechanisms of action with gefitinib and cetuximab and support combined EGFR targeting as a clinically exploitable strategy." @default.
• W2129432386 created "2016-06-24" @default.
• W2129432386 creator A5001910485 @default.
• W2129432386 creator A5011012477 @default.
• W2129432386 creator A5012974257 @default.
• W2129432386 creator A5015190461 @default.
• W2129432386 creator A5020335557 @default.
• W2129432386 creator A5049983097 @default.
• W2129432386 creator A5050698052 @default.
• W2129432386 creator A5058485099 @default.
• W2129432386 creator A5064381901 @default.
• W2129432386 creator A5077169627 @default.
• W2129432386 creator A5085170830 @default.
• W2129432386 date "2004-10-01" @default.
• W2129432386 modified "2023-10-08" @default.
• W2129432386 title "Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)" @default.
• W2129432386 cites W1554880727 @default.
• W2129432386 cites W1964321121 @default.
• W2129432386 cites W1970856815 @default.
• W2129432386 cites W1972870920 @default.
• W2129432386 cites W1979786121 @default.
• W2129432386 cites W1981608739 @default.
• W2129432386 cites W1989170373 @default.
• W2129432386 cites W1995580879 @default.
• W2129432386 cites W2005113904 @default.
• W2129432386 cites W2014868351 @default.
• W2129432386 cites W2015314629 @default.
• W2129432386 cites W2019691808 @default.
• W2129432386 cites W2038882649 @default.
• W2129432386 cites W2039633811 @default.
• W2129432386 cites W2056301613 @default.
• W2129432386 cites W2075310399 @default.
• W2129432386 cites W2077945404 @default.
• W2129432386 cites W2097072725 @default.
• W2129432386 cites W2120282652 @default.
• W2129432386 cites W2324328780 @default.
• W2129432386 cites W4210653281 @default.
• W2129432386 cites W4211075026 @default.
• W2129432386 doi "https://doi.org/10.1158/1078-0432.ccr-04-0870" @default.
• W2129432386 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15475436" @default.
• W2129432386 hasPublicationYear "2004" @default.
• W2129432386 type Work @default.
• W2129432386 sameAs 2129432386 @default.
• W2129432386 citedByCount "269" @default.
• W2129432386 countsByYear W21294323862012 @default.
• W2129432386 countsByYear W21294323862013 @default.
• W2129432386 countsByYear W21294323862014 @default.
• W2129432386 countsByYear W21294323862015 @default.
• W2129432386 countsByYear W21294323862016 @default.
• W2129432386 countsByYear W21294323862017 @default.
• W2129432386 countsByYear W21294323862018 @default.
• W2129432386 countsByYear W21294323862019 @default.
• W2129432386 countsByYear W21294323862020 @default.
• W2129432386 countsByYear W21294323862021 @default.
• W2129432386 countsByYear W21294323862022 @default.
• W2129432386 countsByYear W21294323862023 @default.
• W2129432386 crossrefType "journal-article" @default.
• W2129432386 hasAuthorship W2129432386A5001910485 @default.
• W2129432386 hasAuthorship W2129432386A5011012477 @default.
• W2129432386 hasAuthorship W2129432386A5012974257 @default.
• W2129432386 hasAuthorship W2129432386A5015190461 @default.
• W2129432386 hasAuthorship W2129432386A5020335557 @default.
• W2129432386 hasAuthorship W2129432386A5049983097 @default.
• W2129432386 hasAuthorship W2129432386A5050698052 @default.
• W2129432386 hasAuthorship W2129432386A5058485099 @default.
• W2129432386 hasAuthorship W2129432386A5064381901 @default.
• W2129432386 hasAuthorship W2129432386A5077169627 @default.
• W2129432386 hasAuthorship W2129432386A5085170830 @default.
• W2129432386 hasBestOaLocation W21294323861 @default.
• W2129432386 hasConcept C121608353 @default.
• W2129432386 hasConcept C126322002 @default.
• W2129432386 hasConcept C159654299 @default.
• W2129432386 hasConcept C170493617 @default.
• W2129432386 hasConcept C203014093 @default.
• W2129432386 hasConcept C26375932 @default.
• W2129432386 hasConcept C2776362946 @default.
• W2129432386 hasConcept C2778820342 @default.
• W2129432386 hasConcept C2779438470 @default.
• W2129432386 hasConcept C2779707156 @default.
• W2129432386 hasConcept C2779998722 @default.
• W2129432386 hasConcept C2780580887 @default.
• W2129432386 hasConcept C42362537 @default.
• W2129432386 hasConcept C502942594 @default.
• W2129432386 hasConcept C542903549 @default.
• W2129432386 hasConcept C55493867 @default.
• W2129432386 hasConcept C62112901 @default.
• W2129432386 hasConcept C62478195 @default.
• W2129432386 hasConcept C71924100 @default.
• W2129432386 hasConcept C75217442 @default.
• W2129432386 hasConcept C86803240 @default.
• W2129432386 hasConcept C95444343 @default.
• W2129432386 hasConcept C98274493 @default.
• W2129432386 hasConceptScore W2129432386C121608353 @default.
• W2129432386 hasConceptScore W2129432386C126322002 @default.
• W2129432386 hasConceptScore W2129432386C159654299 @default.
• W2129432386 hasConceptScore W2129432386C170493617 @default.
• W2129432386 hasConceptScore W2129432386C203014093 @default.
• W2129432386 hasConceptScore W2129432386C26375932 @default.

• next